Nat Commun:新途径定位肿瘤

2013-11-13 Nature中文网 Nature中文网

本期Nature Communications上发表的一篇研究论文报告了能将药物定位到癌症组织上的一个多用途化学标签。该标签(理论上能被附着到各种现有抗癌药物上,并能被不同类型的与肿瘤相关的酶通过两个步骤除掉)也许能增强抗癌疗法的疗效。 Nobuhide Ueki及同事报告说,需要两种酶来除掉该标签和释放药物,药物预计主要在癌变组织中出现。组蛋白脱乙酰酶通过将乙酰基从蛋白上除掉来控制基因表达,并

本期Nature Communications上发表的一篇研究论文报告了能将药物定位到癌症组织上的一个多用途化学标签。该标签(理论上能被附着到各种现有抗癌药物上,并能被不同类型的与肿瘤相关的酶通过两个步骤除掉)也许能增强抗癌疗法的疗效。

Nobuhide Ueki及同事报告说,需要两种酶来除掉该标签和释放药物,药物预计主要在癌变组织中出现。组蛋白脱乙酰酶通过将乙酰基从蛋白上除掉来控制基因表达,并且在肿瘤中经常是有活性的;Cathepsin L也已被发现与肿瘤发展和转移相关。通过组蛋白脱乙酰酶将一个乙酰基从这个标签上除掉,会将一个结合点暴露出来,后者允许随后被Cathepsin L劈分。作者将该标签附着到抗癌药物“嘌呤霉素”上,发现带标签的“嘌呤霉素”在一个结肠癌动物模型中在抑制肿瘤生长方面比不带标签的药物更有效。

原文出处:

Nobuhide UekiSiyeon LeeNicole S. SampsonMichael J. Hayman.Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease.Nature Communications    doi:10.1038/ncomms3735



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879749, encodeId=b18318e97493c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Dec 11 20:24:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953346, encodeId=44281953346bf, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Feb 12 06:24:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086666, encodeId=075e20866667c, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 16 11:24:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
    2013-12-11 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879749, encodeId=b18318e97493c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Dec 11 20:24:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953346, encodeId=44281953346bf, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Feb 12 06:24:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086666, encodeId=075e20866667c, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 16 11:24:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879749, encodeId=b18318e97493c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Dec 11 20:24:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953346, encodeId=44281953346bf, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Feb 12 06:24:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086666, encodeId=075e20866667c, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 16 11:24:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
    2014-01-16 liuli5079